As a group, the AD patients showed significantly higher CSF-ERK1/2 concentrations than the nondemented individuals (P < 0.05) and the stable MCI cohort (P < 0.001, Kruskal-Wallis test followed by Dunn's multiple comparison test) (Figure 1). Here, MAPK3 is linked to Alzheimer disease.